The Harmony Prenatal Test is Now Performed in Taiwan by Phoebus Genetics
16 JUNE 16
Roche and Phoebus Genetics Offer Patients Access to Microarray-Based Non-Invasive Prenatal Testing
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that Phoebus Genetics, a preeminent genetics laboratory based in Taiwan, is offering Harmony, the leading global non-invasive prenatal test1 for assessing the probability of fetal trisomy 21, 18, 13, and sex chromosome aneuploidy. As the third commercial laboratory licensed to perform Harmony in the Asia Pacific region, Phoebus is excited to partner with global diagnostics leader, Roche, to offer the exceptional accuracy of the Harmony Prenatal Test in Taiwan.
“After decades of being on the cutting edge of molecular techniques, we are particularly interested in early detection, as demonstrated by our success in the identification of early stage, asymptomatic cancers.” explains Dr. Yi-Ning Su, CEO of Phoebus Genetics. “We view the Harmony Prenatal Test as a key component of our focus on early and accurate detection. Our partnership with Roche Diagnostics provides us the opportunity to offer healthcare providers and expecting parents with exceptional accuracy, affordability, and peace of mind.”
The Harmony Prenatal Test is performed in the Phoebus laboratory with the Harmony Kit and the Ariosa cell-free DNA System.
About the Harmony Test
The Harmony Prenatal Test is a blood screening test for pregnant women that can be used as early as 10 weeks into pregnancy. By evaluating fetal cell-free DNA found in maternal blood, including accurate measurement of the fetal fraction of DNA, the test assesses the probability of Trisomy 21 (Down syndrome) and other common fetal aneuploidies. Harmony has been validated by a robust clinical data set and is supported by clinical studies in more than 23,000 women ranging from 18-48 years of age in all risk categories2. The Harmony Prenatal Test is available in more than 100 countries as a send-out test and has been used to guide clinical care in over 700,000 pregnancies worldwide.
1Harmony™ is a non-invasive prenatal test (NIPT) based on cell-free DNA analysis, and is considered a prenatal screening test, not a diagnostic test. Harmony™ does not screen for potential chromosomal or genetic conditions other than those expressly identified in this document. Before making any treatment decisions, all women should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate
2Norton, M., et al., N Engl J Med 2015; 372:1589-1597. Juneau et al. Fetal Diag Ther. 2014;36(4):282-6. Stokowski et al. Prenatal Diagnosis 2015; 35,1-4.
About Phoebus Genetics
Phoebus Genetics is the leading provider of prenatal diagnostics, genetic testing and counseling in Taiwan. Focused in translational and preventative medicine, Phoebus laboratory services are backed by advanced technologies and academic dedication. Using a variety of novel molecular techniques, Phoebus maintains its commitment to offering tests that play a pivotal role in prevention, diagnosis, and therapeutic monitoring.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognized as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com
All trademarks used or mentioned in this release are protected by law.